Simultaneous detection and quantification of parecoxib and valdecoxib in canine plasma by HPLC with spectrofluorimetric detection: development and validation of a new methodology

被引:12
作者
Saccomanni, G. [2 ]
Giorgi, M. [1 ]
Del Carlo, S. [2 ]
Manera, C. [2 ]
Saba, A. [3 ]
Macchia, M. [2 ]
机构
[1] Univ Pisa, Dept Vet Clin, I-56010 Pisa, Italy
[2] Univ Pisa, Dept Pharmaceut Sci, I-56126 Pisa, Italy
[3] Univ Pisa, Dept Chem & Ind Chem, I-56126 Pisa, Italy
关键词
Parecoxib; Valdecoxib; Plasma; HPLC; Fluorescence; Cox-2; inhibitor; PERFORMANCE LIQUID-CHROMATOGRAPHY; COX-2; QUANTITATION; ETORICOXIB; VAIDECOXIB; INHIBITOR;
D O I
10.1007/s00216-011-5244-4
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Parecoxib is the injectable prodrug of valdecoxib, a cicloxygenase-2 selective drug, currently used in human medicine. Recent studies have suggested both its excellent clinical effectiveness and wide safety profile. The aim of the present study was to develop and validate a new high-performance liquid chromatography (HPLC) with spectrofluorimetric detection method to quantify parecoxib and valdecoxib in canine plasma. Several parameters both in the extraction and the detection method were evaluated. The applicability of the method was determined by administering parecoxib to one dog: the protocol provided the expected pharmacokinetic results. The final mobile phase was acetonitrile: AcONH4 (10 mM; pH 5.0) 55:45, v/v, with a flow rate of 0.4 mL min(-1), and excitation and emission wavelengths of 265 and 375 nm, respectively. The analytical column was a reverse-phase C18 ODS2 3-mu m particle size. Protein precipitation in acidic medium followed by two successive liquid-liquid steps was carried out. The best extraction solvent was cyclohexane:Et2O (3:2, v/v) that gave recoveries ranging from 81.1% to 89.1% and from 94.8% to 103.6% for parecoxib and valdecoxib, respectively. The limits of quantification were 25 and 10 ng mL(-1) for parecoxib and valdecoxib, respectively. The chromatographic runs were specific with no interfering peaks at the retention times of the analytes, as confirmed by HPLC-mass spectrometry experiments. The other validation parameters were in agreement with the European Medicines Evaluation Agency and International Conference on Harmonisation guidelines. In conclusion, this method (extraction, separation and applied techniques) is simple and effective. This is the first time that use of a HPLC with spectrofluorimetric detection technique to simultaneously detect parecoxib and valdecoxib in plasma has been reported. This technique may have applications for pharmacokinetic studies.
引用
收藏
页码:1677 / 1684
页数:8
相关论文
共 30 条
[1]  
[Anonymous], 2009, EMEACHMPEWP192217200
[2]  
[Anonymous], 1996, INT C HARM TECHN REQ
[3]  
BUERGER E, 2010, Patent No. 2010010136
[4]  
BUSCHMANN HH, 2010, Patent No. 2010043412
[5]  
Dalpiaz Anthony S, 2004, Expert Rev Neurother, V4, P165, DOI 10.1586/14737175.4.2.165
[6]  
Gibaldi M., 1982, Pharmacokinetics
[7]  
JIN L, 2010, CHIN J ANESTH, V30, P29
[8]  
Keshetty S, 2006, PHARMAZIE, V61, P245
[9]   Electroencephalographic responses of tramadol, parecoxib and morphine to acute noxious electrical stimulation in anaesthetised dogs [J].
Kongara, Kavitha ;
Chambers, John P. ;
Johnson, Craig B. .
RESEARCH IN VETERINARY SCIENCE, 2010, 88 (01) :127-133
[10]   Glomerular filtration rate after tramadol, parecoxib and pindolol following anaesthesia and analgesia in comparison with morphine in dogs [J].
Kongara, Kavitha ;
Chambers, Paul ;
Johnson, Craig B. .
VETERINARY ANAESTHESIA AND ANALGESIA, 2009, 36 (01) :86-94